Shineway Pharm (02877) saw its share price surge more than 9% in the afternoon session. At the time of writing, the stock was up 8.56% to HK$8.09, with transaction volume reaching HK$27.37 million.

On September 8, the basic medical insurance negotiations wrapped up their morning session, with Shineway Pharm participating in the bidding process by submitting multiple traditional Chinese medicine products, including Shaoyao Gancao Tang Granules and Taohong Siwu Tang Granules.

Notably, the 2026 edition of the National Essential Medicines List officially took effect on September 1. Shineway Pharm successfully secured spots for four traditional Chinese medicine injections and several exclusive traditional Chinese medicine products on the list.

According to the company's interim financial report, revenue for the first half of the year stood at RMB 1.181 billion, down 28.5% year-on-year. Profit for the period reached RMB 469 million, a decline of 23.7% compared to the same period last year. The company proposed a second interim dividend of RMB 0.80 per share.

The group continues to prioritize the expansion of oral formulations as its core development strategy. During the first six months of 2026, oral products accounted for 72.9% of total sales, while injection products contributed the remaining 27.1%.